Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) had its price objective raised by stock analysts at TD Securities from $20.00 to $27.00 in a research note issued to investors on Friday. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. TD Securities’ price target points to a potential upside of 13.21% from the stock’s current price.
A number of other equities analysts have also issued reports on VRX. Mizuho increased their price target on Valeant Pharmaceuticals Intl from $7.00 to $10.00 and gave the company an “underperform” rating in a research note on Friday, December 15th. Piper Jaffray Companies reiterated a “sell” rating and set a $14.00 price objective on shares of Valeant Pharmaceuticals Intl in a research report on Sunday, September 17th. Canaccord Genuity reiterated a “hold” rating and set a $16.00 price objective on shares of Valeant Pharmaceuticals Intl in a research report on Tuesday, October 3rd. HC Wainwright reiterated a “hold” rating and set a $17.00 price objective on shares of Valeant Pharmaceuticals Intl in a research report on Monday, September 18th. Finally, Vetr upgraded Valeant Pharmaceuticals Intl from a “strong sell” rating to a “sell” rating and set a $12.46 price objective for the company in a research report on Thursday, September 28th. Six analysts have rated the stock with a sell rating, ten have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $18.20.
Shares of Valeant Pharmaceuticals Intl (VRX) traded up $0.80 during mid-day trading on Friday, reaching $23.85. The company had a trading volume of 22,330,000 shares, compared to its average volume of 20,590,000. Valeant Pharmaceuticals Intl has a 1-year low of $8.31 and a 1-year high of $24.43. The company has a market cap of $8,320.00, a price-to-earnings ratio of 6.12, a price-to-earnings-growth ratio of 0.68 and a beta of -0.22. The company has a debt-to-equity ratio of 4.84, a current ratio of 1.26 and a quick ratio of 1.03.
In other Valeant Pharmaceuticals Intl news, Director John Paulson purchased 344,216 shares of the stock in a transaction dated Thursday, November 16th. The shares were bought at an average cost of $14.40 per share, with a total value of $4,956,710.40. Following the completion of the transaction, the director now owns 94,559 shares in the company, valued at approximately $1,361,649.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 5.87% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the stock. Riggs Asset Managment Co. Inc. grew its position in Valeant Pharmaceuticals Intl by 118.2% during the third quarter. Riggs Asset Managment Co. Inc. now owns 8,330 shares of the specialty pharmaceutical company’s stock worth $119,000 after buying an additional 4,512 shares in the last quarter. Cetera Investment Advisers acquired a new stake in Valeant Pharmaceuticals Intl during the second quarter worth about $192,000. Harbour Capital Advisors LLC acquired a new stake in Valeant Pharmaceuticals Intl during the third quarter worth about $224,000. American Century Companies Inc. acquired a new stake in Valeant Pharmaceuticals Intl during the third quarter worth about $238,000. Finally, Moors & Cabot Inc. grew its position in Valeant Pharmaceuticals Intl by 32.3% during the second quarter. Moors & Cabot Inc. now owns 15,275 shares of the specialty pharmaceutical company’s stock worth $267,000 after buying an additional 3,725 shares in the last quarter. 49.45% of the stock is currently owned by institutional investors and hedge funds.
About Valeant Pharmaceuticals Intl
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).